Abstract | BACKGROUND: METHODS: This was a 12-week, double blind, placebo controlled, pilot trial involving 30 cocaine dependent subjects. Subjects received either olanzapine (10 mg/day) or identical placebo. Outcome measures included treatment retention, qualitative urine benzoylecgonine tests, cocaine craving, clinical global impression scores, and results from the addiction severity index. RESULTS: Treatment retention was slightly, but significantly, better in the placebo-treated subjects. Placebo-treated subjects were more likely to be abstinent from cocaine during the trial compared to olanzapine-treated subjects, based on urine benzoylecgonine results. Olanzapine was not superior to placebo in any outcome measure. CONCLUSIONS:
|
Authors | Kyle M Kampman, Helen Pettinati, Kevin G Lynch, Thorne Sparkman, Charles P O'Brien |
Journal | Drug and alcohol dependence
(Drug Alcohol Depend)
Vol. 70
Issue 3
Pg. 265-73
(Jun 05 2003)
ISSN: 0376-8716 [Print] Ireland |
PMID | 12757964
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Serotonin Uptake Inhibitors
- Benzodiazepines
- Pirenzepine
- benzoylecgonine
- Cocaine
- Olanzapine
|
Topics |
- Adolescent
- Adult
- Benzodiazepines
- Cocaine
(analogs & derivatives, urine)
- Cocaine-Related Disorders
(drug therapy, urine)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Olanzapine
- Pilot Projects
- Pirenzepine
(analogs & derivatives, therapeutic use)
- Retention, Psychology
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Treatment Outcome
|